• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations now available for on-demand viewing

    11/19/21 10:59:00 AM ET
    $AIH
    $AZN
    $BLCT
    $BTCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIH alert in real time by email

    NEW YORK, Nov. 19, 2021 /CNW/ - Deutsche Bank today announced that the presentations from the November 16th and 17th  Depositary Receipts Virtual Investor Conference ("dbVIC") are now available for on-demand viewing. The event featured presentations from international companies with American Depositary Receipt (ADR) programs in the US.

    Representatives from participating companies based in Australia, China, Germany, France and the UK presented their equity stories and answered audience questions. The presentations are targeted to all types of investors as well as analysts interested in non-US companies.

    To log in, please use the following link: www.adr.db.com/dbvic 

    The company presentations will be available 24/7 for 90 days. Investors, advisors and analysts may download shareholder materials from the "virtual trade booth" for the next three weeks.

    The following companies participated in the conference:

    • Hywin ((HYW)
    • First Pacific ((Hong Kong: 142_HK, OTC:FPAFY)
    • Telstra ((Australia: TLS, OTC:TLSYY)
    • BlueCity Holdings ((BLCT)
    • Yiren Digital ((YRD)
    • Ecofibre ((Australia: EOF, OTC:EOFBY)
    • Ipsen ((Paris: IPN, OTC:IPSEY)
    • Travis Perkins ((London: TPK, OTC:TPRKY)
    • HUTCHMED ((HCM, London: HCM))
    • China Online Education ((COE)
    • NIO ((NIO)
    • Aesthetic Medical International Holdings ((AIH)
    • Quhuo ((QH)
    • AstraZeneca ((London: AZN, NASDAQ:AZN)
    • BIT Mining ((BTCM)
    • Hugo Boss ((Germany: BOSS, OTC:BOSSY)

    In addition to specializing in administering cross-border equity structures such as American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. The Bank offers a broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    Deutsche Bank is sponsoring the Deutsche Bank Depositary Receipt Investor Conference solely for informational purposes. Deutsche Bank does not prepare, review, approve or edit any presentations, statements, documents or other information or materials, whether in written, electronic or verbal form, provided by any company participating in such conference, and disclaims any responsibility for the accuracy or adequacy of any such information or materials. Deutsche Bank is not promoting, endorsing or recommending any company participating in the conference.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© November 2021 Deutsche Bank AG. All rights reserved.

    SOURCE dbVIC - Deutsche Bank Depositary Receipts Virtual Investor Conference

    Cision View original content: http://www.newswire.ca/en/releases/archive/November2021/19/c6486.html

    Get the next $AIH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIH
    $AZN
    $BLCT
    $BTCM

    CompanyDatePrice TargetRatingAnalyst
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    NIO Inc.
    $NIO
    9/23/2025$8.10 → $8.60Buy
    Citigroup
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    NIO Inc.
    $NIO
    9/16/2025$8.50Neutral → Buy
    UBS
    NIO Inc.
    $NIO
    8/26/2025$8.00Neutral → Overweight
    Analyst
    NIO Inc.
    $NIO
    8/1/2025$5.50Neutral → Outperform
    Macquarie
    NIO Inc.
    $NIO
    6/17/2025$3.70 → $3.80Sell → Neutral
    Goldman
    More analyst ratings

    $AIH
    $AZN
    $BLCT
    $BTCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup reiterated coverage on NIO with a new price target

    Citigroup reiterated coverage of NIO with a rating of Buy and set a new price target of $8.60 from $8.10 previously

    9/23/25 10:10:35 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    $AIH
    $AZN
    $BLCT
    $BTCM
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    11/20/25 8:31:49 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    11/17/25 12:52:48 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    11/14/25 10:12:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth

    New capacity at AstraZeneca's Fredrick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines Fourth major US manufacturing investment announced this year, advancing AstraZeneca's historic $50 billion commitment to medicines manufacturing and R&D AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will

    11/21/25 2:05:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Yiren Digital to Report Third Quarter 2025 Financial Results on November 25, 2025

    BEIJING, Nov. 18, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2025 before U.S. market opens on Tuesday, November 25, 2025. Yiren Digital's management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time on November 25, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on November 25, 2025). Participants who wish to join the call should register online in advance of the conference at: https

    11/18/25 2:30:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    Quhuo Expands Use of Blockchain Technology to Enhance Cross-Border Business Operations

    BEIJING, Nov. 13, 2025 /PRNewswire/ -- Quhuo Limited (NASDAQ:QH) ("Quhuo" or the "Company"), a leading gig economy platform focusing on local community-centered services in China, today announced a strategic partnership with blockchain investment and advisory firm Topliquidity Management Limited ("Topliquidity"). Under the agreement, Topliquidity will provide advisory services to Quhuo in connection with its blockchain initiatives and digital currency strategies, strengthening its global expansion. Quhuo International, the Company's overseas division, focuses on vehicle exports. Since its inception in 2023, Quhuo International's business has grown rapidly and established strong partnerships

    11/13/25 6:40:00 AM ET
    $QH
    Real Estate

    $AIH
    $AZN
    $BLCT
    $BTCM
    Leadership Updates

    Live Leadership Updates

    View All

    SOLAI Limited Joins RWA Alliance as a Founding Member to Advance Tokenization of Green Energy Assets

    AKRON, Ohio, Oct. 21, 2025 /PRNewswire/ -- SOLAI Limited (NYSE: SLAI) ("SOLAI" or the "Company"), a leading technology-driven cryptocurrency infrastructure company (previously known as "BIT Mining"), today announced that it has officially joined the Real-World Assets (RWA) Alliance as one of its founding members. The RWA Alliance is dedicated to solving critical industry pain points – such as asset liquidity and opaque valuation – by promoting the tokenization of real-world assets. By leveraging blockchain technology to standardize, divide, and bring transparency to physical assets, the Alliance aims to open up new pathways for the digital transformation of the green energy sector through r

    10/21/25 6:00:00 AM ET
    $BTCM
    EDP Services
    Technology

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Financials

    Live finance-specific insights

    View All

    Yiren Digital to Report Third Quarter 2025 Financial Results on November 25, 2025

    BEIJING, Nov. 18, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast Asia, announced that it plans to release its unaudited financial results for the third quarter ended September 30, 2025 before U.S. market opens on Tuesday, November 25, 2025. Yiren Digital's management will host an earnings conference call at 7:00 a.m. U.S. Eastern Time on November 25, 2025 (or 8:00 p.m. Beijing/Hong Kong Time on November 25, 2025). Participants who wish to join the call should register online in advance of the conference at: https

    11/18/25 2:30:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    NIO Inc. to Report Unaudited Third Quarter 2025 Financial Results on Tuesday, November 25, 2025

    SHANGHAI, Nov. 12, 2025 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE:NIO, HKEX: 9866, SGX: NIO)) ("NIO" or the "Company"), a pioneer and a leading company in the global smart electric vehicle market, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2025 on Tuesday, November 25, 2025, before the open of the U.S. markets. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 25, 2025 (8:00 PM Beijing/Hong Kong/Singapore Time on November 25, 2025). A live and archived webcast of the conference call will be available on the Company's investor relations website at https://ir.nio.com/news-event

    11/12/25 4:30:00 AM ET
    $NIO
    Auto Manufacturing
    Industrials

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

    Baxdrostat demonstrated a statistically significant placebo-adjusted reduction of 13.9 mmHg in night-time ambulatory systolic blood pressure at 12 weeks with a safety profile consistent with the BaxHTN trial Full results presented at the American Heart Association Scientific Sessions 2025 Positive full results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.1 Efficacy was observed throughout the

    11/9/25 4:33:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIH
    $AZN
    $BLCT
    $BTCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    SEC Form SC 13D filed by Quhuo Limited

    SC 13D - QUHUO Ltd (0001781193) (Subject)

    10/15/24 7:19:18 PM ET
    $QH
    Real Estate

    SEC Form SC 13D filed by Quhuo Limited

    SC 13D - QUHUO Ltd (0001781193) (Subject)

    10/15/24 7:17:52 PM ET
    $QH
    Real Estate